The emerging biology of adipose tissue in chronic kidney disease: From fat to facts

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3041-3046

  Axelsson, Jonas ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adipokine; Cytokine; Insulin resistance; Metabolism; Renal disease

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CASPASE 3; FATTY ACID; I KAPPA B KINASE BETA; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; LEPTIN; PHOSPHATIDYLINOSITOL 3 KINASE; SUPPRESSOR OF CYTOKINE SIGNALING; VISFATIN;

ADIPOSE TISSUE; ANOREXIA; B LYMPHOCYTE; BODY MASS; CHRONIC KIDNEY DISEASE; FEEDING BEHAVIOR; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY METABOLISM; LIPID METABOLISM; NOTE; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UREMIA;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; ANOREXIA; BONE AND BONES; ENDOCRINE GLANDS; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; OBESITY; PROGNOSIS; UREMIA;

EID: 52449083107     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn376     Document Type: Note

References (100)

1. Balkau B, Deanfield JE, Despres JP et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007; 116: 1942-1951
2. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550-562
3. Kramer HJ, Saranathan A, Luke A et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-1459
4. Flegal KM, Graubard BI, Williamson DF et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298: 2028-2037
5. Kalantar-Zadeh K, Abbott KC, Salahudeen AK et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543-554
6. Beddhu S, Pappas LM, Ramkumar N et al. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14: 2366-2372
7. Mafra D, Guebre-Egziabher F, Fouque D. Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant 2008 Apr 3; E-pub ahead of print
8. Guilherme A, Virbasius JV, Puri V et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377
9. Ozcan U, Cao Q, Yilmaz E et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-461
10. Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol 2008; 22: 1023-1031
11. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788
12. Kwan BC, Murtaugh MA, Beddhu S. Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 992-998
13. Lee DM, Knight-Gibson C, Samuelsson O et al. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002; 61: 209-218
14. Marchlewska A, Stenvinkel P, Lindholm B et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004; 66: 46-50
15. Heimburger O, Lonnqvist F, Danielsson A et al. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997; 8: 1423-1430
16. Sharma K, Considine RV, Beckie M et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51: 1980-1985
17. Young GA, Woodrow G, Kendall S et al. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition. Nephrol Dial Transplant 1997; 12: 2318-2323
18. Coyne DW, Dagogo-Jack S, Klein S et al. High-flux dialysis lowers plasma leptin concentrations in chronic dialysis patients. Am J Kidney Dis 1998; 32: 1031-1035
19. Nordfors L, Lonnqvist F, Heimburger O et al. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998; 54: 1267-1275
20. Stenvinkel P, Marchlewska A, Pecoits-Filho R et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2004; 65: 274-281
21. Becker B, Kronenberg F, Kielstein JT et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098
22. Menon V, Li L, Wang X et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2599-2606
23. Catena C, Soardo G, Melis A et al. Glucose metabolism in early renal failure. Am J Kidney Dis 2005; 46: 367; author reply-8
24. Eidemak I, Feldt-Rasmussen B, Kanstrup IL et al. Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia 1995; 38: 565-572
25. Crutchlow MF, Robinson B, Pappachen B et al. Validation of steady-state insulin sensitivity indices in chronic kidney disease. Diabetes Care 2007; 30: 1813-1818
26. Foss MC, Gouveia LM, Moyses Neto M et al. Effect of hemodialysis on peripheral glucose metabolism of patients with chronic renal failure. Nephron 1996; 73: 48-53
27. Di Mauro M, Papalia G, Le Moli R et al. Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function. Diabetes Res Clin Pract 2001; 51: 45-50
28. Kobayashi S, Maesato K, Moriya H et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005; 45: 275-280
29. Okada K, Takahashi Y, Okawa E et al. Relationship between insulin resistance and uremic toxins in the gastrointestinal tract. Nephron 2001; 88: 384-386
30. Sautin YY, Nakagawa T, Zharikov S et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584-C596
31. Axelsson J, Bergsten A, Qureshi AR et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69: 596-604
32. Trirogoff ML, Shintani A, Himmelfarb J et al. Body mass index and fatmass are the primary correlates of insulin resistance in nondiabetic stage 3-4 chronic kidney disease patients. Am J Clin Nutr 2007; 86: 1642-1648
33. Sanches FM, Avesani CM, Kamimura MA et al. Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis 2008; 52: 66-73
34. Siew ED, Pupim LB, Majchrzak KM et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007; 71: 146-152
35. Lee SW, Park GH, Lee SW et al. Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant 2007; 22: 2554-2562
36. Bailey JL, Zheng B, Hu Z et al. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 2006; 17: 1388-1394
37. Honda H, Qureshi AR, Axelsson J et al. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr 2007; 86: 633-638
38. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233
39. Ghanim H, Aljada A, Daoud N et al. Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia 2007; 50: 278-285
40. Arkan MC, Hevener AL, Greten FR et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-198
41. Dounousi E, Papavasiliou E, Makedou A et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48: 752-760
42. Kurata A, Nishizawa H, Kihara S et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717-1724
43. Barazzoni R, Bernardi A, Biasia F et al. Low fat adiponectin expression is associated with oxidative stress in nondiabetic humans with chronic kidney disease - impact on plasma adiponectin concentration. Am J Physiol Regul Integr Comp Physiol 2007; 293: R47-R54
44. Richardson DK, Kashyap S, Bajaj M, et al. Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem 2005; 280: 10290-10297
45. Li M, Kim DH, Tsenovoy PL et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008; 57: 1526-1535
46. Ramos LF, Shintani A, Ikizler TA et al. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008; 19: 593-599
47. Axelsson J, Rashid Qureshi A, Suliman ME et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80: 1222-1229
48. Raj DS, Dominic EA, Pai A et al. Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease. Kidney Int 2005; 68: 2338-2344
49. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse gene and its human homolouge. Nature 1994; 372: 425-432
50. Berg AH, Combs TP, Du X et al. The adipocyte-secreted protein Acrp 30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953
51. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrhophy and obesity. Nat Med 2001; 7: 887-888
52. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kB signalling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301
53. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Comm 1999; 257: 79-83
54. Iwashima Y, Horio T, Kumada M et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 2006; 98: 1603-1608
55. Qi L, Doria A, Manson JE et al. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes 2006; 55: 1512-1516
56. Zoccali F, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
57. Tsao TS, Tomas E, Murrey HE et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 2003; 278: 50810-50817
58. Yamauchi T, Nio Y, Maki T et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339
59. Shen YY, Charlesworth JA, Kelly JJ et al. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 2007; 22: 171-178
60. Bluher M, Williams CJ, Kloting N et al. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 2007; 30: 3110-3115
61. Stenvinkel P, Lindholm B, Lönnqvist F et al. Increases in serum leptin during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11: 1303-1309
62. Pecoits-Filho R, Nordfors L, Heimbürger O et al. Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur J Clin Invest 2002; 32: 811-817
63. Don BR, Rosales LM, Levine NW et al. Leptin is a negative acute phase protein in chronic hemodialysis patients. Kidney Int 2001; 59: 1114-1120
64. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119
65. Axelsson J, Qureshi AR, Heimburger O et al. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis 2005; 46: 628-634
66. Hung SC, Tung TY, Yang CS et al. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients. Am J Kidney Dis 2005; 45: 1073-1083
67. Cioffi JA, Shafer AW, Zupancic TJ et al. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nat Med 1996; 2: 585-589
68. Beddhu S, Kimmel PL, Ramkumar N et al. Associations of metabolic syndrome with inflammation in CKD: results from the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2005; 46: 577-586
69. Cheung W, Yu PX, Little BM et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115: 1659-1665
70. Mak RH, Cheung W, Cone RD et al. Leptin and inflammation- associated cachexia in chronic kidney disease. Kidney Int 2006; 69: 794-797
71. Cheung WW, Rosengren S, Boyle DL et al. Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int 2008; 74: 180-186
72. Yang H, Yang T, Baur JA et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007; 130: 1095-1107
73. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430
74. Chen MP, Chung FM, Chang DM et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299
75. Zhang YY, Gottardo L, Thompson R et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 2006; 14: 2119-2126
76. Berndt J, Kloting N, Kralisch S et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916
77. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875
78. Revollo JR, Korner A, Mills KF et al. Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-375
79. Yilmaz MI, Saglam M, Carrero JJ et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-965
80. Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-244
81. Yilmaz MI, Saglam M, Qureshi AR et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008; 23: 1621-1627
82. Stenvinkel P. Inflammation in end-stage renal disease - a fire that burns within. Contrib Nephrol 2005; 149: 185-199
83. Wellen KE, Fucho R, Gregor MF et al. Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 2007; 129: 537-548
84. Charriere G, Cousin B, Arnaud E et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem 2003; 278: 9850-9855
85. Axelsson J, Qureshi AR, Suliman ME et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80: 1222-1229
86. Axelsson J, Wang X, Ketteler M et al. Is Fetuin-A/alpha2-Heremans- Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease? Am J Nephrol 2008; 28: 669-676
87. Fain JN, Madan AK, Hiler ML et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-2282
88. Clement K, Viguerie N, Poitou C et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. Faseb J 2004; 18: 1657-1669
89. Axelsson J, Moller HJ, Witasp A et al. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis 2006; 48: 916-925
90. Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469
91. Griffith JF, Yeung DK, Antonio GE et al. Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology 2005; 236: 945-951
92. Di Iorgi N, Rosol M, Mittelman SD et al. Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. J Clin Endocrinol Metab 2008; 93: 2281-2286
93. Schiller PC, D'Ippolito G, Brambilla R et al. Inhibition of gap-junctional communication induces the trans-differentiation of osteoblasts to an adipocytic phenotype in vitro. J Biol Chem 2001; 276: 14133-14138
94. Shinoda Y, Yamaguchi M, Ogata N et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006; 99: 196-208
95. Gordeladze JO, Drevon CA, Syversen U et al. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 2002; 85: 825-836
96. Tobian L. Hypertension and obesity. N Engl J Med 1978; 298: 46-48
97. Sarzani R, Salvi F, Dessi-Fulgheri P et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26: 831-843
98. Alvarez GE, Beske SD, Ballard TP et al. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533-2536
99. Nogueiras R, Wiedmer P, Perez-Tilve D et al. The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest 2007; 117: 3475-3488
100. Gadegbeku CA, Shrayyef MZ, LaPorte FB et al. Lipids enhance alpha1-adrenoceptor pressor sensitivity in patients with chronic kidney disease. Am J Kidney Dis 2004; 44: 446-454